Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An announcement from Chimeric Therapeutics Ltd. ( (AU:CHM) ) is now available.
Chimeric Therapeutics has issued 466,666,665 new ordinary shares on 31 December 2025, expanding its share capital without providing a prospectus or other disclosure document, in reliance on the provisions of section 708A of the Corporations Act. The company affirmed that it is up to date with its financial reporting and continuous disclosure obligations and stated there is no excluded information requiring disclosure, signalling that the large capital issuance is being conducted within existing regulatory frameworks and without undisclosed market-sensitive information for investors.
The most recent analyst rating on (AU:CHM) stock is a Hold with a A$0.01 price target. To see the full list of analyst forecasts on Chimeric Therapeutics Ltd. stock, see the AU:CHM Stock Forecast page.
More about Chimeric Therapeutics Ltd.
Chimeric Therapeutics Limited (ASX: CHM) is an Australian biotechnology company focused on developing innovative therapeutic products, with its ordinary shares listed on the Australian Securities Exchange. The company operates under Australian corporate and securities law, including continuous disclosure and financial reporting obligations.
Technical Sentiment Signal: Sell
Current Market Cap: A$10.93M
Find detailed analytics on CHM stock on TipRanks’ Stock Analysis page.